BackGeneFerm Biotechnology , Ltd. Overview

GeneFerm Biotechnology , Ltd. Long Term Debt

GeneFerm Biotechnology , Ltd.'s long-term debt is $270M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$266.29M
↓ 8.22% YoYΔ $-23.84M vs prior year quarter

Peer trimmed avg / median

Loading

GeneFerm Biotechnology , Ltd. Long Term Debt History

Loading

GeneFerm Biotechnology , Ltd. vs. peers: Long Term Debt Comparison

Loading

GeneFerm Biotechnology , Ltd. Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

GeneFerm Biotechnology , Ltd. (1796.TWO) FAQ

The latest long-term debt for 1796.TWO is $270M as of September 2026. That compares with $290M in the prior-year period — down 8.2% year over year. Investors often review this figure alongside GeneFerm Biotechnology , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 1796.TWO's long-term debt moved from $290M to $270M — a 8.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in GeneFerm Biotechnology , Ltd.'s operating scale or balance-sheet position.

A long-term debt figure of $270M for 1796.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 1796.TWO's long-term debt ($270M), review year-over-year change from $290M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.